The EMA approves a new formulation of a levodopa-carbidopa combination to treat moderate-to-severe motor fluctuations in patients with Parkinson’s disease.

The Food and Drug Administration authorized Gain Therapeutics' investigational new drug application for a Parkinson's disease treatment, clearing the way for the biotechnology company to launch a ...

Globally, Parkinson's has a global disease burden that is expected to double by 2050, with cases rising from 8.5 million in 2021 to 17.5 million. These figures have been highlighted in the study ...

The U.S. Food and Drug Administration (FDA) cleared Gain Therapeutics to begin a mid-stage clinical trial of its experimental ...

Parkinson's disease is the second most common neurodegenerative disease, affecting over 10 million people worldwide. Some forms of Parkinson's disease are characterized by an inability of cells to ...

How well our brain functions depends heavily on the performance of our nerve cells. That is why they are regularly checked for their proper function -- defective cell components are marked, disposed ...

Simon Fraser University researchers are using a new approach to brain imaging that could improve how drugs are prescribed to treat Parkinson's disease. The new study, published in the journal Movement ...

After the shock of being diagnosed with Parkinson’s disease a year ago, Pearl Bartlett has found herself facing an unexpected ...

Plastic waste has long been viewed as one of the world's most persistent environmental challenges. Yet researchers have now ...

A medication developed in the 1950s to treat Parkinson's disease may offer a powerful new tool in the fight against tuberculosis (TB), according to new research from the University of British Columbia ...